Ketamine/temsirolimus
| Combination of | |
|---|---|
| Ketamine | NMDA receptor antagonist |
| Temsirolimus | mTOR inhibitor |
| Clinical data | |
| Other names | FREE-001; FREE001; Temsirolimus/ketamine |
Ketamine/temsirolimus (developmental code name FREE001 or FREE-001) is a combination of ketamine, an NMDA receptor antagonist, and temsirolimus, a mammalian target of rapamycin (mTOR) inhibitor, which is under development for the treatment of major depressive disorder.[1][2][3][4] It is being developed to prolong the antidepressant effects of ketamine and esketamine, by 2 to 3 times, from 2 to 7 days to 14 days in terms of preliminary clinical findings.[3] The combination is being developed by Freedom Biosciences.[1][2][3][4] As of April 2024, it is in phase 2 clinical trials.[1][2][3][4]
See also
References
- ^ a b c "Ketamine/Temsirolimus". AdisInsight. 30 April 2024. Retrieved 28 February 2025.
- ^ a b c "Delving into the Latest Updates on FREE-001 with Synapse". Synapse. 23 January 2025. Retrieved 28 February 2025.
- ^ a b c d Cornall J (23 August 2022). "Freedom Biosciences exits stealth with $10.5M financing to develop mental health treatments". Labiotech.eu. Retrieved 28 February 2025.
Program FREE001 is a ketamine treatment demonstrated in clinical trials to have more durable effects than ketamine. A phase 2 investigational study showed the combination provided 14 days of antidepressant effects, two to three times longer than the usual two to seven days of effects from ketamine alone.
- ^ a b c "FDA Approves IND Application for Freedom's Ketamine-Based Combination Therapy". Psychedelic Medical News - News coverage and analysis of the latest developments in the field of psychedelic health care. 26 April 2024. Retrieved 28 February 2025.